Loading…
Loading…
KLTO (Klotho Neurosciences, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
KLTO does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for KLTO and 80,000+ other tickers.
See exactly how KLTO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for KLTO and 80,000+ other tickers.
Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders. Their leading gene therapy assets encompass AMI-101, which is designed for the management or prevention of Alzheimer's disease, and AMI-202, aimed at treating or averting amyotrophic lateral sclerosis. Formerly known as Anew Medical, Inc., the company underwent a name change to Klotho Neurosciences, Inc. in September 2024. The firm's main office is situated in Omaha, Nebraska.
Klotho Neurosciences (NASDAQ: KLTO - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends. Analyst Ratings This is a breakdown of
Klotho Neurosciences (NASDAQ: KLTO - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings. Risk and Volatility Klotho Neurosciences has a
Company to hold investor webcast on March 12, 2026 at 4:15PM ET to discuss its expanded focus on critical minerals development in Greenland CHARLOTTE, N.C., March 12, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO) ("Klotho" or the "Company") today announces that it changed its corporate name to Greenland Mines Ltd and its stock ticker to "GRML" effective at market open today, Thursday, March 12, 2026.
/PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO) ("Klotho" or the "Company") today announces that it is changing its corporate name to Greenland Mines
Transaction delivers shareholders direct ownership in one of the largest undeveloped palladium-gold deposits on Earth, establishing a new western champion in critical mineral supply security; Company to rebrand as Greenland Mines CHARLOTTE, N.C. and NUUK, Greenland, March 4, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO) ("Klotho" or the "Company") today announces the acquisition of Greenland Mines Corp. ("Greenland Mines" or "GMC"), a privately held Delaware corporation that controls an 80% interest in, and an option to acquire the remaining 20% of, the Skaergaard Project in Southeast Greenland — one of the largest and most significant undeveloped palladium, gold, and platinum deposits in the world.